18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma
Journal of Nuclear Medicine · 2024-02 · 65 (2) · 206-212
DOI: 10.2967/jnumed.123.266283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 04.01.2024. Verfasst von Xiang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal, Quinolines. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses associated with PDAC are often characterized by hypometabolism. Here, we investigated 18F-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in evaluation of PDAC and compared the findings with those obtained using 18F-FDG.
Methods
Sixty-two PDAC patients underwent 18F-FAPI-04 PET/CT and 18F-FDG PET/CT. Identification of primary lesions, lymph node (LN) metastasis, and distant metastasis (DM) by these methods was evaluated, and TNM staging was performed. Correlation between SUVmax of the primary lesion and treatment response was explored in patients who received systemic therapy.
Results
18F-FAPI-04 PET/CT identified all patients with PDAC; 18F-FDG PET/CT missed 1 patient. Tracer uptake was higher in 18F-FAPI-04 PET/CT than in 18F-FDG PET/CT in primary tumors (10.63 vs. 2.87, P < 0.0001), LN metastasis (2.90 vs. 1.43, P < 0.0001), and DM (liver, 6.11 vs. 3.10, P = 0.002; peritoneal, 4.70 vs. 2.08, P = 0.015). The methods showed no significant difference in the T staging category, but the N and M values were significantly higher for 18F-FAPI-04 PET/CT than for 18F-FDG PET/CT (P = 0.002 and 0.008, respectively). Thus, 14 patients were upgraded, and only 1 patient was downgraded, by 18F-FAPI-04 PET/CT compared with 18F-FDG PET/CT. A high SUVmax of the primary tumor did not correlate with treatment response for either 18F-FAPI-04 or 18F-FDG.
Conclusion
18F-FAPI-04 PET/CT performed better than 18F-FDG PET/CT in identification of primary tumors, LN metastasis, and DM and in TNM staging of PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
- Department of Nuclear Medicine, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Radiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; and.
- Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; liangtingbo@zju.edu.cn shirleybai@zju.edu.cn.
- Zhejiang University Cancer Center, Hangzhou, China.
Zitieren
APA
Li, X., Lu, N., Lin, L., Chen, Y., Yang, S., Wang, H., Liu, X., Wu, C., Xue, X., Su, X., Bai, X., & Liang, T. (2024). 18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. Journal of Nuclear Medicine, 65(2), 206-212. https://doi.org/10.2967/jnumed.123.266283
Vancouver
Li X, Lu N, Lin L, Chen Y, Yang S, Wang H, et al. 18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. Journal of Nuclear Medicine. 2024;65(2):206-212. doi:10.2967/jnumed.123.266283
BibTeX
@article{Li2024,
author = {Li, Xiang and Lu, Na and Lin, Lili and Chen, Yiwen and Yang, Shuye and Wang, Huatao and Liu, Xinyuan and Wu, Chengyi and Xue, Xing and Su, Xinhui and Bai, Xueli and Liang, Tingbo},
title = {18 F-FAPI-04 Outperforms 18 F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {2},
pages = {206--212},
doi = {10.2967/jnumed.123.266283}
}
EUVIMED